{
  "id": "breast-cancer-cdk46-by-regimen-main",
  "display_name": "ER+/HER2- MBC Regimen Margins",
  "cohort": "ER+/HER2- Metastatic Breast Cancer, 2nd Line, by Regimen (2024–2025)",
  "insight_type": "Margin Analysis",
  "summary": "CDK4/6i + Fulvestrant regimen delivers 35% higher margins than other regimens for ER+/HER2- MBC patients. A 12% increase in utilization could yield $210,000/year.",
  "chart": {
    "type": "bar",
    "unit": "regimen",
    "data": [
      { "name": "CDK4/6i + Fulvestrant", "value": 85, "gap": 35, "highlight": true },
      { "name": "CDK4/6i + AI", "value": 72, "gap": 22, "highlight": false },
      { "name": "Fulvestrant Mono", "value": 50, "gap": 0, "highlight": false },
      { "name": "Chemo-based", "value": 42, "gap": -8, "highlight": true },
      { "name": "AI Mono", "value": 38, "gap": -12, "highlight": false }
    ],
    "benchmark": 50,
    "nccn_target": 50
  },
  "financial_impact": {
    "annual_opportunity": "$210,000/year",
    "math": "$210,000/year = 12% increase × 50 patients × $35,000 margin difference"
  },
  "clinical_impact": {
    "description": "CDK4/6i regimens provide substantial clinical benefits over monotherapy options.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+13.5 months",
        "description": "Superior progression-free survival for CDK4/6i + Fulvestrant"
      },
      {
        "type": "OS",
        "value": "+10.2 months",
        "description": "Overall survival benefit vs. monotherapy"
      },
      {
        "type": "ORR",
        "value": "+24%",
        "description": "Higher objective response rate"
      },
      {
        "type": "QoL",
        "value": "+18%",
        "description": "Better quality of life scores"
      },
      {
        "type": "ToT",
        "value": "+45%",
        "description": "Longer time on treatment"
      }
    ],
    "quantitative": "+13.5 months PFS"
  },
  "peer_comparison": {
    "description": "Your practice uses CDK4/6i + Fulvestrant in only 28% of eligible patients, compared to 45% among peers. This represents a $335,000/year margin opportunity.",
    "peer_benchmark": 45,
    "financial_impact": {
      "annual_opportunity": "$335,000/year",
      "math": "$335,000/year = 17% increase × 56 patients × $35,000 margin difference"
    },
    "action_steps": [
      {
        "text": "Schedule regimen selection training for oncology team",
        "icon": "users"
      },
      {
        "text": "Develop CDK4/6i + Fulvestrant clinical pathway",
        "icon": "document"
      },
      {
        "text": "Implement regimen margin dashboard by provider",
        "icon": "chart"
      },
      {
        "text": "Create automated alerts for eligible patients",
        "icon": "alert"
      }
    ]
  },
  "weighted_score": 94,
  "action_steps": [
    {
      "text": "Identify patients eligible for regimen optimization",
      "icon": "flag"
    },
    {
      "text": "Update order sets to prioritize higher-margin regimens",
      "icon": "document"
    },
    {
      "text": "Implement regimen-specific financial counseling",
      "icon": "clipboard"
    },
    {
      "text": "Analyze payer mix impact on regimen margins",
      "icon": "chart-line"
    }
  ],
  "suggestions": [
    {
      "text": "Review prior authorization processes for CDK4/6i regimens",
      "icon": "document"
    }
  ],
  "drilldowns": [
    {
      "label": "View by Provider",
      "cohort": "ER+/HER2- MBC, 2L, by Provider Regimen Selection",
      "jsonFile": "breast-cancer-cdk46-by-provider-regimen.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Payer Coverage",
      "cohort": "ER+/HER2- MBC, 2L, by Payer Regimen Coverage",
      "jsonFile": "breast-cancer-cdk46-by-payer-regimen.json",
      "drilldownLevel": 1
    },
    {
      "label": "Margin Detail Analysis",
      "cohort": "ER+/HER2- MBC, 2L, Regimen Margin Components",
      "jsonFile": "breast-cancer-cdk46-regimen-margins.json",
      "drilldownLevel": 1
    }
  ]
} 